Breast and Ovarian Cancer Genetic Kit
Cannalogix Foundation is proud to bring to its members (new and old) the Breast and Ovarian Cancer Genetic Kit. The Breast and Ovarian Cancer Genetic Kit uses DNA to look at several factors to determine a person’s predisposition to Breast and Ovarian Cancer. We are proud to be a part of this research and will be updating you more as technology advances.
Breast cancer is the second most common cancer in women after skin cancer with around 230,000 cases in a year, with around 40,000 deaths.
Around 12% of women are expected to develop breast cancer in their lifetime.
Around 12% of women are expected to develop breast cancer in their lifetime. Ovarian cancer is the fifth-leading cause of cancer related deaths in women and in 2014, approximately 22,000 new cases were diagnosed in the US with around 14,000 deaths.
Genetic changes in several genes have been associated with increased risk of breast and/or ovarian cancer. These include mutations in BRCA1, BRCA2, TP53, PTEN, STK11, CHEK2, ATM, BRIP1, PALB2 and RAD51C genes.
‘s breast and ovarian cancer kit has been designed to assess genetic changes in all of the 10 genes to identify risk for breast and ovarian cancer development.